JP2007520565A - デヒドロフェニラヒスチン及びそれらの類似体、並びにデヒドロフェニラヒスチン及びそれらの類似体の合成 - Google Patents

デヒドロフェニラヒスチン及びそれらの類似体、並びにデヒドロフェニラヒスチン及びそれらの類似体の合成 Download PDF

Info

Publication number
JP2007520565A
JP2007520565A JP2006552282A JP2006552282A JP2007520565A JP 2007520565 A JP2007520565 A JP 2007520565A JP 2006552282 A JP2006552282 A JP 2006552282A JP 2006552282 A JP2006552282 A JP 2006552282A JP 2007520565 A JP2007520565 A JP 2007520565A
Authority
JP
Japan
Prior art keywords
substituted
atom
nitro
group
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006552282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007520565A5 (fr
Inventor
エー． パラディノ，マイケル
ケネス ロイド，ジョージ
良雄 林
ニコルソン，ベンジャミン
Original Assignee
ネレアス ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネレアス ファーマシューティカルズ インコーポレイテッド filed Critical ネレアス ファーマシューティカルズ インコーポレイテッド
Publication of JP2007520565A publication Critical patent/JP2007520565A/ja
Publication of JP2007520565A5 publication Critical patent/JP2007520565A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2006552282A 2004-02-04 2005-02-04 デヒドロフェニラヒスチン及びそれらの類似体、並びにデヒドロフェニラヒスチン及びそれらの類似体の合成 Pending JP2007520565A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54207304P 2004-02-04 2004-02-04
US62426204P 2004-11-01 2004-11-01
PCT/US2005/003636 WO2005077940A1 (fr) 2004-02-04 2005-02-04 Dehydrophenylahistines et leurs analogues et la synthese des dehydrophenylahistines et de leurs analogues

Publications (2)

Publication Number Publication Date
JP2007520565A true JP2007520565A (ja) 2007-07-26
JP2007520565A5 JP2007520565A5 (fr) 2008-04-03

Family

ID=34864489

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006552282A Pending JP2007520565A (ja) 2004-02-04 2005-02-04 デヒドロフェニラヒスチン及びそれらの類似体、並びにデヒドロフェニラヒスチン及びそれらの類似体の合成

Country Status (9)

Country Link
EP (1) EP1711487A1 (fr)
JP (1) JP2007520565A (fr)
KR (1) KR101228104B1 (fr)
AU (1) AU2005212399B2 (fr)
BR (1) BRPI0506655A (fr)
CA (1) CA2553630A1 (fr)
IL (1) IL176932A0 (fr)
NZ (1) NZ548659A (fr)
WO (1) WO2005077940A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016536352A (ja) * 2013-10-11 2016-11-24 ビヨンドスプリング インコーポレイテッド プリナブリン及びタキサンの組合せがん治療
JP2018520178A (ja) * 2015-07-13 2018-07-26 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリン組成物
JP2018199726A (ja) * 2018-09-26 2018-12-20 ビヨンドスプリング インコーポレイテッド プリナブリン及びタキサンの組合せがん治療
US10238650B2 (en) 2015-03-06 2019-03-26 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
US10357491B2 (en) 2015-03-06 2019-07-23 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
US11400086B2 (en) 2017-02-01 2022-08-02 Beyondspring Pharmaceuticals, Inc. Method of reducing chemotherapy-induced neutropenia

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
CN100540548C (zh) 2002-08-02 2009-09-16 尼瑞斯药品公司 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
WO2007035841A1 (fr) * 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogues de deshydrophenylahistines et utilisation therapeutique de ceux-ci
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
MY193968A (en) * 2015-02-12 2022-11-03 Beyondspring Pharmaceuticals Inc Use of plinabulin in combination with immune checkpoint inhibitors
CA3013467A1 (fr) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions contenant du tucaresol ou ses analogues
KR20230018545A (ko) 2016-06-06 2023-02-07 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
WO2018028420A1 (fr) * 2016-08-12 2018-02-15 青岛海洋生物医药研究院股份有限公司 Forme polycristalline de composé de type déhydrophénylahistine, son procédé de fabrication et de purification et son application.
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
CN110603037A (zh) * 2017-03-13 2019-12-20 大连万春布林医药有限公司 普那布林的组合物及其用途
JP7350015B2 (ja) 2018-01-24 2023-09-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリンの投与による血小板減少症を軽減するための組成物および方法
CN108524442B (zh) * 2018-06-05 2022-01-28 深圳海王医药科技研究院有限公司 一种抗肿瘤药物的注射剂及其制备方法
CA3234699A1 (fr) * 2021-10-07 2023-04-13 Beyondspring Pharmaceuticals, Inc. Methodes de traitement de cancers et de tumeurs

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053290A1 (fr) * 2000-01-18 2001-07-26 Nippon Steel Corporation Inhibiteurs de la division cellulaire et procede de production de ces inhibiteurs
US20020028819A1 (en) * 2000-05-09 2002-03-07 Che-Ming Teng Piperazinedione compounds
JP2002507612A (ja) * 1998-03-25 2002-03-12 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 細胞毒性海洋天然産物であるハリミドおよび該ハリミドの誘導体
US20020143021A1 (en) * 1998-11-12 2002-10-03 Kenji Fukumoto Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
JP4616649B2 (ja) * 2002-08-02 2011-01-19 ネレアス ファーマシューティカルズ インコーポレイテッド デヒドロフェニラヒスチンおよびそれらの類似体、ならびにデヒドロフェニラヒスチンおよびそれらの類似体の合成

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3318789A1 (de) * 1983-05-24 1984-11-29 Eduard Gerlach GmbH Chemische Fabrik, 4990 Lübbecke Deodorant
GB9402807D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002507612A (ja) * 1998-03-25 2002-03-12 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 細胞毒性海洋天然産物であるハリミドおよび該ハリミドの誘導体
US20020143021A1 (en) * 1998-11-12 2002-10-03 Kenji Fukumoto Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
WO2001053290A1 (fr) * 2000-01-18 2001-07-26 Nippon Steel Corporation Inhibiteurs de la division cellulaire et procede de production de ces inhibiteurs
US20020028819A1 (en) * 2000-05-09 2002-03-07 Che-Ming Teng Piperazinedione compounds
JP4616649B2 (ja) * 2002-08-02 2011-01-19 ネレアス ファーマシューティカルズ インコーポレイテッド デヒドロフェニラヒスチンおよびそれらの類似体、ならびにデヒドロフェニラヒスチンおよびそれらの類似体の合成

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HIROSHI KANZAKI 他: "A Novel Potent Cell Cycle Inhibitor Dehydrophenylahistin - Enzymatic Synthesis and Inhibitory Activi", THE JOURNAL OF ANTIBIOTICS, vol. 55(12), JPN6011006655, 2002, pages 1042 - 1047, ISSN: 0001843865 *
医薬品製造指針２００１, JPN6011050516, 2001, pages 243 - 244, ISSN: 0002025331 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016536352A (ja) * 2013-10-11 2016-11-24 ビヨンドスプリング インコーポレイテッド プリナブリン及びタキサンの組合せがん治療
US10238650B2 (en) 2015-03-06 2019-03-26 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
US10357491B2 (en) 2015-03-06 2019-07-23 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
JP2018520178A (ja) * 2015-07-13 2018-07-26 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリン組成物
US10550104B2 (en) 2015-07-13 2020-02-04 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
JP2021181497A (ja) * 2015-07-13 2021-11-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリン組成物
US11400086B2 (en) 2017-02-01 2022-08-02 Beyondspring Pharmaceuticals, Inc. Method of reducing chemotherapy-induced neutropenia
JP2018199726A (ja) * 2018-09-26 2018-12-20 ビヨンドスプリング インコーポレイテッド プリナブリン及びタキサンの組合せがん治療

Also Published As

Publication number Publication date
KR101228104B1 (ko) 2013-02-01
IL176932A0 (en) 2006-12-10
KR20060124743A (ko) 2006-12-05
AU2005212399B2 (en) 2011-09-22
WO2005077940A1 (fr) 2005-08-25
AU2005212399A1 (en) 2005-08-25
BRPI0506655A (pt) 2007-05-08
EP1711487A1 (fr) 2006-10-18
NZ548659A (en) 2011-01-28
CA2553630A1 (fr) 2005-08-25

Similar Documents

Publication Publication Date Title
JP2007520565A (ja) デヒドロフェニラヒスチン及びそれらの類似体、並びにデヒドロフェニラヒスチン及びそれらの類似体の合成
JP4616649B2 (ja) デヒドロフェニラヒスチンおよびそれらの類似体、ならびにデヒドロフェニラヒスチンおよびそれらの類似体の合成
US7935704B2 (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US8247552B2 (en) Analogs of dehydrophenylahistins and their therapeutic use
US8129527B2 (en) Analogs of dehydrophenylahistins and their therapeutic use
WO2007035841A9 (fr) Analogues de deshydrophenylahistines et utilisation therapeutique de ceux-ci
CN1934101B (zh) 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
WO2011084962A1 (fr) Analogues de déshydrophénylahistines
CN101633655A (zh) 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
MXPA06008810A (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110509

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110927